Acceleron Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Acceleron Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XLRN

Author's Avatar
Sep 30, 2021

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Acceleron Pharma Inc. (NASDAQ: XLRN) to Merck & Co., Inc. for $180.00 per share in cash is fair to Acceleron shareholders.